Search PubMed⌕ Search

Biomedical subjects

M Rowland

Publications and source records attributed to M Rowland.

At least 253 records · Page 14Linked to original sources

Influence of acute viral hepatitis on phenytoin kinetics and protein binding.

Patients with liver disease are thought to have abnormal responses to drugs metabolized by the liver, although supportive evidence is sparse. The influence of acute viral hepatitis on the pharmacokinetics and protein binding of phenytoin (DPH) was examined in 5 patients. A longitudinal study design was used so that each patient acted as his own control. DPH clearance was unaffected by acute viral hepatitits over theconcentration range studie, but the percentage of unboudn DPH increased by an average of nearly one-third during acute viral hepatitis. A small decline in serum albumin concentration and elevated serum bilirubin levels may be responsible for the alterations in protein bindig. These results indicate that acute inflammatory liver disease has complex and perhaps paradoxical effects on durg disposition. Clinical and laboratory observations including plasma durg concentrations, still provide the best means for adjusting dosage regimens in patients with fluctuating hepatic function.

Bilirubin↗

Warfarin-phenylbutazone interaction in man: a long term multiple dose study.

The effect of phenylbutazone on the disposition of warfarin was studied in a subject given warfarin daily for one month. During concomitant phenylbutazone administration, the total plasma warfarin concentration declined from 4.2 to 2.0 mg/L. In contrast, the unbound warfarin plasma concentration rose from 0.020 to 0.033 mg/L. The plasma concentration and daily urinary excretion of 7-hydroxywarfarin fell during phenylbutazone administration. Warfarin is administered as a racemate. Exclusive to and the major metabolic route of the more potent S-isomer is 7-hydroxylation. It is concluded that inhibition of S-warfarin metabolism can help explain the increased anticoagulation seen when phenylbutazone is added to the dosage regimen of a patient stabilized on warfarin.

Adult↗